touchIMMUNOLOGY joins Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) at EAACI 2021 to discuss the rationale behind avapritinib for advanced systemic mastocytosis and the results of the PATHFINDER study.
Questions
- Could you give us a brief overview of the disease burden of advanced systemic mastocytosis and the unmet needs in its treatment? (0:26)
- What was the rationale for investigating avapritinib in the treatment of patients with advanced systemic mastocytosis? (1:04)
- Could you tell us a little about the PATHFINDER study and its findings? (1:39)
- How clinically meaningful are these benefits? (2:35)
Disclosures: In relation to this video interview, MM has received honoraria for advice as well as institutional research support by Blueprint and Celldex.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2021 EAACI Annual Meeting.
